De La Cruz, L. M., McDonald, E. S., Mick, R., Datta, J., Nocera, N. F., Xu, S., . . . Czerniecki, B. J. (2017). Anti-HER2 CD4+ T-Helper Type 1 Immune Response is Superior to Breast MRI for Assessing Response to Neoadjuvant Therapy in Patients with HER2-Positive Breast Cancer. Annals of Surgical Oncology, 24(4), 1057-1063. https://doi.org/10.1245/s10434-016-5651-z
Chicago-referens (17:e uppl.)De La Cruz, Lucy M., Elizabeth S. McDonald, R. Mick, Jashodeep Datta, Nadia F. Nocera, Shuwen Xu, Carla S. Fisher, och Brian J. Czerniecki. "Anti-HER2 CD4+ T-Helper Type 1 Immune Response Is Superior to Breast MRI for Assessing Response to Neoadjuvant Therapy in Patients with HER2-Positive Breast Cancer." Annals of Surgical Oncology 24, no. 4 (2017): 1057-1063. https://doi.org/10.1245/s10434-016-5651-z.
MLA-referens (9:e uppl.)De La Cruz, Lucy M., et al. "Anti-HER2 CD4+ T-Helper Type 1 Immune Response Is Superior to Breast MRI for Assessing Response to Neoadjuvant Therapy in Patients with HER2-Positive Breast Cancer." Annals of Surgical Oncology, vol. 24, no. 4, 2017, pp. 1057-1063, https://doi.org/10.1245/s10434-016-5651-z.
